Johnson & Johnson - International Biopharmaceutical Industry

Current Edition

news

Pressed by Wall Street, pharma executives signal openness to M&A

Pharmaceutical executives are getting asked the same question. With many large drugmakers flush with cash, and valuations of publicly traded biotech companies crashin...

10 February 2022 news Johnson & Johnson | M&A

Continue Reading →

news

J&J foresees end to not-for-profit sales of coronavirus vaccine

J&J has recorded far fewer sales of its coronavirus vaccine than competitors Pfizer and Moderna, partly due to its not-for-profit pricing but also to a series of ...

22 October 2021 news coronavirus vaccine | J&J

Continue Reading →

news

Pfizer, marking fast research pace, starts key trial of RSV vaccine

A vaccine against RSV has proven elusive despite decades of attempts. Pfizer is moving at a surprisingly quick pace to catch up to rivals led by GlaxoSmithKline, who ...

3 September 2021 news GlaxoSmithKline | GSK

Continue Reading →

news

FDA grants full approval to Pfizer, BioNTech’s coronavirus vaccine

The Food and Drug Administration on Monday granted full approval to Pfizer and BioNTech's coronavirus vaccine, a long-awaited decision that government officials hope ...

27 August 2021 news BioNTech | coronavirus vaccine

Continue Reading →

International Biopharmaceutical Industry

IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.

Current Edition

Upcoming Events

Advertisement

Pressed by Wall Street, pharma executives signal openness to M&A

J&J foresees end to not-for-profit sales of coronavirus vaccine

Pfizer, marking fast research pace, starts key trial of RSV vaccine

FDA grants full approval to Pfizer, BioNTech’s coronavirus vaccine

International Biopharmaceutical Industry